Current Report Filing (8-k)
December 14 2016 - 4:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
December 14, 2016
STELLAR BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified
in its charter)
British Columbia, Canada
|
|
000-54598
|
|
N/A
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
332 E. Scott Street
Port Hueneme, California 93041
(Address of principal executive offices)
(Zip Code)
(805) 488-2800
(Registrant’s telephone number, including
area code)
Not applicable.
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On December 14, 2016, Stellar Biotechnologies,
Inc. issued a press release announcing its financial results for its fiscal year ended September 30,
2016 (the “Earnings Release”). The full text of the Earnings Release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference. The information furnished herein and therein shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except
as shall be expressly set forth by specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press release issued by Stellar Biotechnologies, Inc. dated December 14, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Stellar Biotechnologies, Inc.
|
|
|
|
|
|
|
Date: December 14, 2016
|
By:
|
/s/ Kathi Niffenegger
|
|
Name:
|
Kathi Niffenegger
|
|
Title:
|
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
99.1
|
|
Press release issued by Stellar Biotechnologies, Inc. dated December 14, 2016.
|
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stellar Biotechnologies Inc. (NASDAQ:SBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024